Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415–455. https://doi.org/10.1016/0022-510x(73)90175-5

Google Scholar 

Bidgood R, Zubelzu M, Ruiz-Ortega JA, Morera-Herreras T (2024) Automated procedure to detect subtle motor alterations in the balance beam test in a mouse model of early Parkinson’s disease. Sci Rep 14(1):862. https://doi.org/10.1038/s41598-024-51225-1

Google Scholar 

Blesa J, Foffani G, Dehay B, Bezard E, Obeso JA (2022) Motor and non-motor circuit disturbances in early Parkinson disease: which happens first? Nat Rev Neurosci 23(2):115–128. https://doi.org/10.1038/s41583-021-00542-9

Google Scholar 

Bunnell E, Saltonstall E, Pederson A, Baxter C, Ramicciotti E, Robinson N, Sandholm P, O Niel A, Raber J (2025) Extinction of contextual fear memory and passive avoidance memory and subsequent anxiety-like and depressive-like behavior of A53T and A53T-L444P mice. Genes 16(9):1004. https://doi.org/10.3390/genes16091004

Google Scholar 

Burke RE, O’Malley K (2013) Axon degeneration in Parkinson’s disease. Exp Neurol 246:72–83. https://doi.org/10.1016/j.expneurol.2012.01.011

Google Scholar 

Caminiti SP, Presotto L, Baroncini D, Garibotto V, Moresco RM, Gianolli L, Volonté MA, Antonini A, Perani D (2017) Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson’s disease. Neuroimage Clin 14:734–740. https://doi.org/10.1016/j.nicl.2017.03.011

Google Scholar 

Choong CJ, Mochizuki H (2022) Neuropathology of α-synuclein in Parkinson’s disease. Neuropathology 42(2):93–103. https://doi.org/10.1111/neup.12812

Google Scholar 

Coakeley S, Martens KE, Almeida QJ (2014) Management of anxiety and motor symptoms in Parkinson’s disease. Expert Rev Neurother 14(8):937–946. https://doi.org/10.1586/14737175.2014.936388

Google Scholar 

Costa G, Sisalli MJ, Simola N, Della Notte S, Casu MA, Serra M, Pinna A, Feliciello A, Annunziato L, Scorziello A, Morelli M (2020) Gender differences in neurodegeneration, neuroinflammation and Na+-Ca2+ exchangers in the female A53T Transgenic mouse model of Parkinson’s disease. Front Aging Neurosci 12:118. https://doi.org/10.3389/fnagi.2020.00118

Google Scholar 

Delic V, Chandra S, Abdelmotilib H, Maltbie T, Wang S, Kem D, Scott HJ, Underwood RN, Liu Z, Volpicelli-Daley LA, West AB (2018) Sensitivity and specificity of phospho-Ser129 α-synuclein monoclonal antibodies. J Comp Neurol 526(12):1978–1990. https://doi.org/10.1002/cne.24468

Google Scholar 

Deng I, Wiese MD, Zhou XF, Bobrovskaya L (2021) The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinson’s disease in C57BL/6 mice. Neurotoxicology 85:254–264. https://doi.org/10.1016/j.neuro.2021.05.015

Google Scholar 

Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301. https://doi.org/10.1093/brain/114.5.2283

Google Scholar 

Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, Nuber S, Masliah E (2013) Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein. Am J Pathol 182(3):940–953. https://doi.org/10.1016/j.ajpath.2012.11.018

Google Scholar 

Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, Grant LM, Ciucci MR, MacKeigan JP, Sortwell CE (2013) Morphological and behavioral impact of AAV2/­5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS ONE 8(11):e81426. https://doi.org/10.1371/journal.pone.0081426

Google Scholar 

Goodwin NL, Choong JJ, Hwang S et al (2024) Simple Behavioral Analysis (SimBA) as a platform for explainable machine learning in behavioral neuroscience. Nat Neurosci 27(7):1411–1424. https://doi.org/10.1038/s41593-024-01649-9

Google Scholar 

Hong JY, Lee JS, Kim SH, Lee PH (2025) A model of l-dopa-induced dyskinesia in parkinsonian mice produced by aav vector-mediated overexpression of Α-Synuclein. Exp Neurol 389:115264. https://doi.org/10.1016/j.expneurol.2025.115264

Google Scholar 

Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB (2017) AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease. Acta Neuropathol Commun 5(1):11. https://doi.org/10.1186/s40478-017-0416-x

Google Scholar 

Jakes R, Crowther RA, Lee VM, Trojanowski JQ, Iwatsubo T, Goedert M (1999) Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett 269(1):13–16. https://doi.org/10.1016/s0304-3940(99)00411-5

Google Scholar 

Kang KW, Choi SM, Kim BC (2022) Gender differences in motor and non-motor symptoms in early Parkinson disease. Medicine 101(3):e28643. https://doi.org/10.1097/MD.0000000000028643

Google Scholar 

Kim R, Lee J, Kim Y, Kim A, Jang M, Kim HJ, Jeon B, Kang UJ, Fahn S (2018) Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson’s disease: An analysis of the PPMI cohort. Parkinsonism Relat Disord 51:49–54. https://doi.org/10.1016/j.parkreldis.2018.02.047

Google Scholar 

Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med 318(14):876–880. https://doi.org/10.1056/NEJM198804073181402

Google Scholar 

Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM (2010) Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson’s disease. Mol Neurodegener 5:43. https://doi.org/10.1186/1750-1326-5-43

Google Scholar 

Koprich JB, Kalia LV, Brotchie JM (2017) Animal models of α-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci 18(9):515–529. https://doi.org/10.1038/nrn.2017.75

Google Scholar 

Lamontagne-Proulx J, Coulombe K, Morissette M, Rieux M, Calon F, Di Paolo T, Soulet D (2023) Sex and age differences in a progressive synucleinopathy mouse model. Biomolecules 13(6):977. https://doi.org/10.3390/biom13060977

Google Scholar 

Landeck N, Buck K, Kirik D (2017) Toxic effects of human and rodent variants of alpha-synuclein in vivo. Eur J Neurosci 45(4):536–547. https://doi.org/10.1111/ejn.13493

Google Scholar 

Lee JJ, Ham JH, Lee PH, Sohn YH (2015) Gender differences in age-related striatal dopamine depletion in Parkinson’s disease. J Mov Disord 8(3):130–135. https://doi.org/10.14802/jmd.15031

Google Scholar 

Liang Y, Zhou L, Liu H, Huang X, Li Y, Li X, Huang S (2025) G protein-coupled estrogen receptor activation exerts protective effects via modulating brain and gut NLRP3 inflammasome in Parkinson’s disease. Exp Neurobiol 34(5):200–213. https://doi.org/10.5607/en25022

Google Scholar 

Mirelman A, Bonato P, Camicioli R, Ellis TD, Giladi N, Hamilton JL, Hass CJ, Hausdorff JM, Pelosin E, Almeida QJ (2019) Gait impairments in Parkinson’s disease. Lancet Neurol 18(7):697–708. https://doi.org/10.1016/S1474-4422(19)30044-4

Google Scholar 

Musacchio T, Yin J, Kremer F, Koprich JB, Brotchie JM, Volkmann J, Ip CW (2022) Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson’s disease. Behav Brain Res 432:113968. https://doi.org/10.1016/j.bbr.2022.113968

Google Scholar 

Nath T, Mathis A, Chen AC, Patel A, Bethge M, Mathis MW (2019) Using DeepLabCut for 3D markerless pose estimation across species and behaviors. Nat Protoc 14(7):2152–2176. https://doi.org/10.1038/s41596-019-0176-0

Google Scholar 

Nuber S, Harmuth F, Kohl Z, Adame A, Trejo M, Schönig K, Zimmermann F, Bauer C, Casadei N, Giel C, Calaminus C, Pichler BJ, Jensen PH, Müller CP, Amato D, Kornhuber J, Teismann P, Yamakado H, Takahashi R, Winkler J, Masliah E, Riess O (2013) A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats. Brain 136(2):412–432. https://doi.org/10.1093/brain/aws358

Google Scholar 

Oliveras-Salvá M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D’Hooge R, Van den Haute C, Baekelandt V (2013) rAAV2/­7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol Neurodegener 8:44. https://doi.org/10.1186/1750-1326-8-44

Google Scholar 

Pakkenberg B, Møller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H (1991) The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54(1):30–33. https://doi.org/10.1136/jnnp.54.1.30

Google Scholar 

Paxinos G, Franklin K (2004) The mouse brain in stereotaxic coordinates. Elsevier Science, Amsterdam

Google Scholar 

Phan JA, Stokholm K, Zareba-Paslawska J, Jakobsen S, Vang K, Gjedde A, Landau AM, Romero-Ramos M (2017) Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson’s disease. Sci Rep 7(1):1–17. https://doi.org/10.1038/s41598-017-06724-9

Google Scholar 

Quintino L, Gubinelli F, Sarauskyte L, Arvidsson E, Davidsson M, Lundberg C, Heuer A (2022) Automated quantification of neuronal swellings in a preclinical rodent model of Parkinson’s disease detects region-specific changes in pathology. J Neurosci Methods 378:109640. https://doi.org/10.1016/j.jneumeth.2022.109640

Google Scholar 

Rajsombath MM, Nam AY, Ericsson M, Nuber S (2019) Female sex and brain-selective estrogen benefit α-synuclein tetramerization and the PD-like motor syndrome in 3K transgenic mice. J Neurosci 39(38):7628–7640. https://doi.org/10.1523/JNEUROSCI.0313-19.2019

Google Scholar 

Rugbjerg K, Christensen J, Tjønneland A, Olsen JH (2013) Exposure to estrogen and women’s risk for Parkinson’s disease: a prospective cohort study in Denmark. Parkinsonism Relat Disord 19(4):457–460. https://doi.org/10.1016/j.parkreldis.2013.01.008

Google Scholar 

Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y (1989) Striatal dopamine deficiency in Parkinson’s disease: role of aging. Ann Neurol 26(4):551–557. https://doi.org/10.1002/ana.410260409

Google Scholar 

Sharma M, Burré J (2023) α-Synuclein in synaptic function and dysfunction. Trends Neurosci 46(2):153–166. https://doi.org/10.1016/j.tins.2022.11.007

Google Scholar 

Sirabella R, Sisalli MJ, Costa G, Omura K, Ianniello G, Pinna A, Morelli M, Di Renzo GM, Annunziato L, Scorziello A (2018) NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson’s Disease. Cell Death Dis 9(7):725. https://doi.org/10.1038/s41419-018-0775-7

Google Scholar 

Solla P, Cannas A, Ibba FC, Loi F, Corona M, Orofino G, Marrosu MG, Marrosu F (2012) Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson’s disease. J Neurol Sci 323(1–2):33–39. https://doi.org/10.1016/j.jns.2012.07.026

Google Scholar 

Song LK, Ma KL, Yuan YH, Mu Z, Song XY, Niu F, Han N, Chen NH (2015) Targeted overexpression of Α-synuclein by rAAV2/­1 vectors induces progressive nigrostriatal degeneration and increases vulnerability to MPTP in mouse. PLoS ONE 10(6):e0131281. https://doi.org/10.1371/journal.pone.0131281

Google Scholar 

Thadathil N, Xiao J, Hori R, Alway SE, Khan MM (2021) Brain selective estrogen treatment protects dopaminergic neurons and preserves behavioral function in MPTP-induced mouse model of Parkinson’s disease. J Neuroimmune Pharmacol 16(3):667–678. https://doi.org/10.1007/s11481-020-09972-1

Google Scholar 

Tofaris GK, Reitböck PG, Humby T, Lambourne SL, O’Connell M, Ghetti B, Gossage H, Emson PC, Wilkinson LS, Goedert M, Spillantini MG (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein(1-120): implications for lewy body disorders. J Neurosci 26(15):3942–3950. https://doi.org/10.1523/JNEUROSCI.4965-05.2006